ijms-logo

Journal Browser

Journal Browser

Special Issue "The Molecular Basis of Therapeutic Resistance of Brain Tumor"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 15 May 2021.

Special Issue Editor

Prof. BuHyun Youn
E-Mail Website
Guest Editor
Department of Biological Sciences, Pusan National University, Busan, Korea
Interests: brain tumor; glioblastoma; therapeutic resistance; cancer metabolism; signaling transduction; oncogene; radiotherapy

Special Issue Information

Dear Colleagues,

Brain tumor is one of the formidable tumor types due to its unique spatial and physiological features. The preferred treatment for the brain tumor is surgical elimination, which is usually followed by chemo- and radiotherapy to prevent recurrence. Therefore, therapeutic resistance is a major obstruction to achieving successful control of brain tumors. Although related studies have been performed over several decades, there has been little remarkable advance in brain tumor treatment—especially absence in malignant brain tumor. Currently, wide-ranging screening and analytical techniques help investigators to discover novel therapeutic targets with reliable molecular mechanisms in various types of tumors. Furthermore, the combination of target inhibitors with classical therapies could marginally elevate therapeutic efficacy. In the context of brain tumors, recent studies have underscored the alterations in cellular signaling transduction, metabolic pathways, oncogenic gene expressions, and microenvironments, leading to the acquisition of therapeutic resistance and malignancy. Therefore, a deeper investigation about the molecular mechanisms of these events is prompted to suggest ways to overcome the contemporary limitations of treatments.

In this Special Issue, we shall discuss the recent advances in molecular mechanisms around the therapeutic resistance of brain tumors derived from genetic/epigenetic, metabolic, and microenvironmental alterations for next-generation therapeutic strategies. The types of research invited include basic/translational research and reviews.

Prof. BuHyun Youn
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Brain tumor
  • Therapeutic resistance
  • Molecular mechanisms
  • Signaling transduction
  • Cancer metabolism
  • Oncogene
  • Microenvironments
  • Epigenetics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function
Int. J. Mol. Sci. 2021, 22(6), 2982; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22062982 - 15 Mar 2021
Viewed by 331
Abstract
Glioblastoma multiforme (GBM) is a malignant primary brain tumor with poor patient prognosis. Although the standard treatment of GBM is surgery followed by chemotherapy and radiotherapy, often a small portion of surviving tumor cells acquire therapeutic resistance and become more aggressive. Recently, altered [...] Read more.
Glioblastoma multiforme (GBM) is a malignant primary brain tumor with poor patient prognosis. Although the standard treatment of GBM is surgery followed by chemotherapy and radiotherapy, often a small portion of surviving tumor cells acquire therapeutic resistance and become more aggressive. Recently, altered kinase expression and activity have been shown to determine metabolic flux in tumor cells and metabolic reprogramming has emerged as a tumor progression regulatory mechanism. Here we investigated novel kinase-mediated metabolic alterations that lead to acquired GBM radioresistance and malignancy. We utilized transcriptomic analyses within a radioresistant GBM orthotopic xenograft mouse model that overexpresses the dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3). We find that within GBM cells, radiation exposure induces DYRK3 expression and DYRK3 regulates mammalian target of rapamycin complex 1 (mTORC1) activity through phosphorylation of proline-rich AKT1 substrate 1 (PRAS40). We also find that DYRK3 knockdown inhibits dynamin-related protein 1 (DRP1)-mediated mitochondrial fission, leading to increased oxidative phosphorylation (OXPHOS) and reduced glycolysis. Importantly, enforced DYRK3 downregulation following irradiation significantly impaired GBM cell migration and invasion. Collectively, we suggest DYRK3 suppression may be a novel strategy for preventing GBM malignancy through regulating mitochondrial metabolism. Full article
(This article belongs to the Special Issue The Molecular Basis of Therapeutic Resistance of Brain Tumor)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: The role of long non-coding RNAs in Brain Tumor

Title: What is Epigenetic drivers for brain tumors?

Title: Molecular epigenetic landscape to understand the link from gut to brain

Title: Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function

Title: The molecular mechanisms of current platinum anticancer drug resistance in brain tumors

Title: The role of radiation-induced circulating miRNAs in brain tumor

Title: Epigenetic Modulation of MGMT in Human Glioma Cells Resistant to Temozolomide

Title: Lomeguatrib increases the radiosensitivity of MGMT unmethylated human Glioblastoma multiforme cell lines

Title: Evaluation of Haptoglobin and Its proteoforms as Glioblastoma marker

Title: Mechanisms of temozolomide resistance in GBM

Title: The Molecular Basis of Therapeutic Resistance of Brain Tumor

Title: Metabolome shift in both metastatic brain cancer cells and astrocytes which may contribute tumor microenvironment

Title: Treatment-Induced Cytostasis in the Therapeutic Resistance of Brain Tumors

Title: Brain metastasis from renal cell carcinoma after targeted therapy: the role of immunotherapy regarding on brain microenvironment 

Title: Role of WNT pathway in therapeutic resistance in glioblastoma

Title: Therapeutic delivery strategies and combinatory treatment for glioblastoma - an update

Title: Molecular mechanisms of drug resistance of glioblastoma

Back to TopTop